Pharma Industry Lists Multiple Failings Of EU Regulatory System
EFPIA Wants Less Complexity, More Flexibility In Drug Evaluations
The European Commission’s plans for overhauling the EU medicines legislation have elicited a number of proposals from the pharmaceutical industry to improve the regulatory framework, including streamlining the committee system, improving the use of expedited evaluation pathways, and expanding the European Medicines Agency’s role in assessing drug/device combination products.
